Key facts
- This page summarizes Bay Shore Trust's Form 4 filing for Telomir Pharmaceuticals, Inc. (TELO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Feb 2024, 16:11.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
Purchase
Purchase
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
These securities are owned directly by the Bay Shore Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Brian McNulty ("Mr. McNulty") as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Footnote F2
These securities are owned directly by the MIRALOGX, LLC, of which the Trust holds all of the membership interests, and indirectly by Mr. McNulty as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Footnote F3
These securities are owned directly by a trust for which Mr. McNulty serves as trustee. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities.
Footnote F4
These securities are owned directly by Mr. McNulty.